2 new hepatitis C drugs to be available in November in Egypt

CAIRO: Minister of Health Adel al-Adawy declared that two new hepatitis C medications, Harvoni and Viekira, are to be accessible at the hepatitis treatment focuses by next November, youm7 reported Wednesday.

There are 2.3 million hepatitis C patients in Egypt, while 996,642 patients connected on the National's site Committee for the Control of Viral Hepatitis to be dealt with by Sovaldi until last June, as per Adawy.

He included that 85,536 patients were furnished with the treatment until the end of June.

As per the treatment conventions of hepatitis C treatment focuses, reaction rate of Sovaldi is 92.7 percent, said Adawy.

Egypt is wanting to offer Sovaldi, the American-designed hepatitis C treatment, at a cost of 600 EGP ($80) per bottle, which is four times less expensive than its U.S. equal, Adawy told Youm7 June 13.

As indicated by the United Nations Population Fund, Egypt has the most astounding rate of hepatitis C disease on the planet; 14.7 percent of the populace between ages 15-49 have tried positive for the infection.

In September 2014, Egypt imported 225,000 Sovaldi bottles from the U.S., produced by the Gilead Science Company, furthermore a got a comparative sum in March 2015.

The sticker cost for the medication is roughly $1,000 per pill in the U.S. market, with a 12-week course of treatment adding up to $84,000 as per Forbes magazine.

However the producer has given stores of the drug to Egypt for a 99% markdown, with Cairo financing a significant part of the remaining expenses to give treatment to its subjects.